ANHYDRON
LOE ApproachingNDAORALTABLET
Approved
Aug 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANHYDRON is an oral small-molecule tablet approved by Eli Lilly in 1963 with an unknown mechanism of action and indication profile. The exact therapeutic area and patient population cannot be determined from available data.
LOE Approaching
Product is in advanced lifecycle stage with LOE approaching; commercial teams are likely in defensive/optimization mode with reduced headcount investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ANHYDRON presents minimal career growth opportunities with zero linked job openings and a product in its final commercial lifecycle stages. Career impact is primarily defensive—maintaining compliance, managing generic transition, and supporting legacy customer relationships rather than driving innovation or expansion.
Product Manager (Legacy)Regulatory Specialist
Worked on ANHYDRON at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.